prof. Bogusław Szewczyk
The aim of the project is to develop vaccine candidates based on mRNA/VLP technology against one of three zoonotic viral pathogens (SARS-CoV-2 coronavirus, Tick-Borne Encephalitis Virus, TBEV and West Nile virus, WNV) that are of great importance to human health around the world.
The development path started from designing the mRNA encoding for virus antigens, through the potential vaccine candidate evaluation, preclinical and I phase of the clinical studies. The whole project is divided into 10 tasks. They include a research stage using mRNA/VLP technology and a development stage of the production and analysis process on a laboratory and pilot scale.
The suspected project effect combines the advantages of both mRNA and VLPs: high effectiveness, long-lasting, the beginning of the dosing regimen, the possibility of storage in convenient conditions and safety in addition to control and pediatric use.
Project co-financed by the state from the Medical Research Agency, in the competition: Development of new technologies using RNA technology
The consortium consists of:
– Adamed Sp. Zoo. (Project leader)
– University of Gdansk
– Institute of Biotechnology and Biophysics of the Polish Academy of Sciences
Project value PLN 87,517,519.25, including PLN 11,382,750.00 for UG
Funding PLN 58,494,498.19